Ovarian germ cell tumor epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 16: | Line 16: | ||
* In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | * In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide. | ||
* The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | * The prevalence of [disease/malignancy] is estimated to be [number] cases annually. | ||
===Dysgerminoma=== | |||
*This tumor accounts for less than 1% of all ovarian cancers. | |||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | *In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | ||
| Line 25: | Line 26: | ||
*Patients of all age groups may develop mature teratoma. However, they tend to present between 20 to 30 years of age at a greater extent.<ref name="Yayla AbideBostancı Ergen2018">{{cite journal|last1=Yayla Abide|first1=Çiğdem|last2=Bostancı Ergen|first2=Evrim|title=Retrospective analysis of mature cystic teratomas in a single center and review of the literature|journal=Journal of Turkish Society of Obstetric and Gynecology|volume=15|issue=2|year=2018|pages=95–98|issn=1307699X|doi=10.4274/tjod.86244}}</ref> | *Patients of all age groups may develop mature teratoma. However, they tend to present between 20 to 30 years of age at a greater extent.<ref name="Yayla AbideBostancı Ergen2018">{{cite journal|last1=Yayla Abide|first1=Çiğdem|last2=Bostancı Ergen|first2=Evrim|title=Retrospective analysis of mature cystic teratomas in a single center and review of the literature|journal=Journal of Turkish Society of Obstetric and Gynecology|volume=15|issue=2|year=2018|pages=95–98|issn=1307699X|doi=10.4274/tjod.86244}}</ref> | ||
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | *The incidence of [disease name] increases with age; the median age at diagnosis is [#] years. | ||
* | Dysgerminoma | ||
*Dysgerminoma commonly affects individuals younger than 30 years of age in 85% of cases.<ref name="VicusBeiner2010">{{cite journal|last1=Vicus|first1=Danielle|last2=Beiner|first2=Mario E.|last3=Klachook|first3=Shany|last4=Le|first4=Lisa W.|last5=Laframboise|first5=Stephane|last6=Mackay|first6=Helen|title=Pure dysgerminoma of the ovary 35 years on: A single institutional experience|journal=Gynecologic Oncology|volume=117|issue=1|year=2010|pages=23–26|issn=00908258|doi=10.1016/j.ygyno.2009.12.024}}</ref> | |||
*[Chronic disease name] is usually first diagnosed among [age group]. | *[Chronic disease name] is usually first diagnosed among [age group]. | ||
*[Acute disease name] commonly affects [age group]. | *[Acute disease name] commonly affects [age group]. | ||
| Line 33: | Line 36: | ||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | ||
===Gender=== | ===Gender=== | ||
* | *Seminoma is the male counterpart of dysgerminoma in women.<ref name="VicusBeiner2010">{{cite journal|last1=Vicus|first1=Danielle|last2=Beiner|first2=Mario E.|last3=Klachook|first3=Shany|last4=Le|first4=Lisa W.|last5=Laframboise|first5=Stephane|last6=Mackay|first6=Helen|title=Pure dysgerminoma of the ovary 35 years on: A single institutional experience|journal=Gynecologic Oncology|volume=117|issue=1|year=2010|pages=23–26|issn=00908258|doi=10.1016/j.ygyno.2009.12.024}}</ref> | ||
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | *[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1. | ||
Revision as of 14:46, 28 February 2019
|
Ovarian germ cell tumor Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian germ cell tumor epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Ovarian germ cell tumor epidemiology and demographics |
|
FDA on Ovarian germ cell tumor epidemiology and demographics |
|
CDC on Ovarian germ cell tumor epidemiology and demographics |
|
Ovarian germ cell tumor epidemiology and demographics in the news |
|
Blogs on Ovarian germ cell tumor epidemiology and demographics |
|
Risk calculators and risk factors for Ovarian germ cell tumor epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
Mature teratoma
- The incidence of mature/benign teratoma is between 1.2 to 14.2 cases per 100,000 individuals worldwide.[1]
- The germ cell tumors of the ovary consist approximately one-fourth of ovarian neoplasms and a great majority of them are benign.
Prevalence
Mature teratoma
- Mature teratoma is the most common ovarian germ cell tumor tumor and accounts for 95% of ovarian teratomas.[2]
- The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
- In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
- The prevalence of [disease/malignancy] is estimated to be [number] cases annually.
Dysgerminoma
- This tumor accounts for less than 1% of all ovarian cancers.
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
Mature teratoma
- Patients of all age groups may develop mature teratoma. However, they tend to present between 20 to 30 years of age at a greater extent.[3]
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
Dysgerminoma
- Dysgerminoma commonly affects individuals younger than 30 years of age in 85% of cases.[4]
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- Seminoma is the male counterpart of dysgerminoma in women.[4]
- [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Westhoff C, Pike M, Vessey M (July 1988). "Benign ovarian teratomas: a population-based case-control study". Br. J. Cancer. 58 (1): 93–8. PMC 2246492. PMID 3166898.
- ↑ Ulbright, Thomas M (2005). "Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues". Modern Pathology. 18: S61–S79. doi:10.1038/modpathol.3800310. ISSN 0893-3952.
- ↑ Yayla Abide, Çiğdem; Bostancı Ergen, Evrim (2018). "Retrospective analysis of mature cystic teratomas in a single center and review of the literature". Journal of Turkish Society of Obstetric and Gynecology. 15 (2): 95–98. doi:10.4274/tjod.86244. ISSN 1307-699X.
- ↑ 4.0 4.1 Vicus, Danielle; Beiner, Mario E.; Klachook, Shany; Le, Lisa W.; Laframboise, Stephane; Mackay, Helen (2010). "Pure dysgerminoma of the ovary 35 years on: A single institutional experience". Gynecologic Oncology. 117 (1): 23–26. doi:10.1016/j.ygyno.2009.12.024. ISSN 0090-8258.